Results 251 to 260 of about 2,706,111 (311)

TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer. [PDF]

J Immunother Cancer
Wu B, Thant W, Bitman E, Liu T, Liu J, Paschalis EI, Patel BK, Nawrocki C, Xu KH, Nieman LT, Ting DT, de Gois Macedo B, Cheng Y, Jiang K, Sun F, Thimmiah N, Sun S, Abelman RO, Bossuyt VI, Isakoff SJ, Spring LM, Bardia A, Ellisen LW.   +22 more
europepmc   +1 more source

Regulation of mitochondrial ROS by C15ORF48 in a basal cell subpopulation contributes to chemotherapy resistance in TNBC. [PDF]

Sci Adv
Jiang Y, Abdulkareem NM, Rinkenbaugh AL, Qi Y, Wall SW, Zhang X, Shao J, Jeter-Jones S, Cai S, Hancock FB, Echeverria GV, Chang JT, Piwnica-Worms H.   +12 more
europepmc   +1 more source

Rational modulation of immune mechanisms synergizes the anti-tumor effects of targeted radiation therapy in pre-clinical models. [PDF]

Front Immunol
Wirtz T, Lee C, Ram S, Xie T, Mojtahedzadeh S, Streiner N, Noorbehesht K, Manzuk LK, Rohner A, Cabral E, Bonato V, Affolter T, Kraus M, Dillon C, Giddabasappa A.   +14 more
europepmc   +1 more source

TNFRSF17 as a complementary biomarker to PD-L1 for predicting the response to immunotherapy in urothelial bladder cancer. [PDF]

PLoS One
Chen J, Li B, Gan Y, Li P.
europepmc   +1 more source

Glancing at the role of Toxoplasma gondii in neuro-oncology: from risk factor to therapeutic target. [PDF]

Infect Agent Cancer
Eissa MM, Ali NAF, El Skhawy N.
europepmc   +1 more source

Characterization of Oncogenic and Immunogenic Profiling in Patients with Breast Cancer Tumors After Radiation Therapy. [PDF]

Int J Mol Sci
Niture S, Vargas CE, Chumsri S, Kachergus JM, Sriramanujam S, Thotala D, Jaboin J, Seneviratne D.   +7 more
europepmc   +1 more source